国浩律师（深圳）事务所 关于 深圳华大基因股份有限公司 二〇二五年第二次临时股东会 之 法律意见书 广东省深圳市福田区深南大道 6008 号特区报业大厦 42、41、31DE、2403、2405，邮编：518034 42、41、31DE、2403、2405, Tequbaoye Building 6008 Shennan Avenue Shenzhen 518034, China 电话/Tel: +86 755 83515666 传真/Fax: +86 755 83515333 网址/Website: http://www.grandall.com.cn 二〇二五年十一月 1 深圳华大基因股份有限公司 2025 年第二次临时股东会法律意见书 国浩律师（深圳）事务所 关于深圳华大基因股份有限公司 二〇二五年第二次临时股东会之 法律意见书 编号：GLG/SZ/A2626/FY/2025-1476 号 致：深圳华大基因股份有限公司 国浩律师（深圳）事务所（以下简称本所）接受深圳华大基因股份有限公司 （以下简称公司、贵公司）委托，指派本所律师出席公司 2025 年第二次临时股 东会（以下简称本次股东会）。本所律师根据 ...

Core Viewpoint - The gene sequencing sector has shown a positive performance, with a 1.28% increase, ranking sixth among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Market Performance - As of November 12, the gene sequencing concept rose by 1.28%, with 45 stocks increasing in value, including notable gainers such as Kaineng Health (20% limit up), Nanjing Xinbai, and Zhongyuan Harmony, which also hit the limit up [1]. - The top gainers in the sector included Danna Biology (9.99%), Yihong Biological (6.71%), and Heyuan Biological (3.63%) [1]. - Conversely, the sector saw declines in stocks like Wavelength Optoelectronics, Gongjin Co., and Hanwang Technology, which fell by 3.16%, 2.40%, and 1.77% respectively [1]. Group 2: Capital Flow - The gene sequencing sector attracted a net inflow of 643 million yuan from major funds, with 31 stocks receiving net inflows, and 7 stocks exceeding 30 million yuan in net inflow [2]. - Zhongyuan Harmony led the net inflow with 220 million yuan, followed by Nanjing Xinbai and Kaineng Health with 176 million yuan and 174 million yuan respectively [2]. - The net inflow ratios for Nanjing Xinbai, Zhongyuan Harmony, and Jinyu Medical were 34.82%, 25.74%, and 18.18% respectively, indicating strong investor interest [3].

Core Viewpoint - The article discusses the significant impact of Guangzhou's policy on the development of the gene industry, highlighting the role of BGI Genomics in advancing gene testing accessibility and innovation in the sector [1][3]. Policy Impact - Guangzhou has prioritized the cell and gene industry as one of its six future industries, which is seen as a crucial step for the sector's growth [3]. - The policy elevates the industry from enterprise-led innovation to government-level design, providing a supportive framework for innovation and development [3][4]. - The implementation of this policy is viewed as a critical move for the localization of national macro policies [3]. Company Strategy - BGI Genomics is leveraging local policy advantages to expand its business, including establishing subsidiaries and developing domestic testing platforms [3][4]. - The company aims to make gene testing accessible to everyone by optimizing costs and enhancing technology [5][7]. - BGI Genomics plans to utilize Guangzhou's rich medical resources for clinical trials and the introduction of new diagnostic technologies [4][6]. Cost and Accessibility - High costs of gene testing have been a barrier to widespread adoption, but BGI Genomics is working to reduce these costs through self-sufficiency in technology and materials [5][6]. - Government initiatives, such as free prenatal screening programs, are seen as effective pathways to increase accessibility [5][6]. - The integration of gene testing into medical insurance is expected to broaden access, despite potential short-term revenue pressures for companies [6][7]. Data Assetization - The value of gene data is increasingly recognized, with a focus on data assetization while ensuring compliance and privacy [8]. - BGI Genomics is collaborating with Shenzhen Data Exchange to ensure strict data security measures [8]. - The company envisions using gene data to support the development of innovative drugs and early screening for rare diseases, aiming to reduce treatment costs [8]. Future Outlook - The gene industry is anticipated to experience new growth opportunities due to policy support, technological advancements, and the increasing value of data [8]. - BGI Genomics is committed to enhancing its competitiveness and contributing to societal progress through accessible gene testing [8].

Core Insights - The National Data Bureau is actively engaging with private enterprises to enhance the development of the data industry and artificial intelligence, emphasizing the importance of private sector involvement in the digital economy [1] Group 1: Industry Overview - As of November 10, there are 751,900 existing big data service-related companies in China, primarily concentrated in new first-tier and first-tier cities, accounting for 30.08% and 21.3% respectively [2][5] - Over 40% of these companies belong to the information transmission, software, and information technology services sector, with a significant 40.14% share, followed by scientific research and technical services at 26.2% [6][5] Group 2: Registration Trends - The annual registration of big data service-related companies has shown an upward trend over the past decade, with 186,600 companies registered this year, surpassing the total registration for the previous year [9][6] - In the first ten months of this year, 181,700 companies were registered, reflecting a year-on-year growth of 28.28% [9] Group 3: Future Projections - The Chinese data industry is projected to reach a scale of 5.8 trillion yuan by 2025, with an expected annual growth rate of over 15%, potentially exceeding 13 trillion yuan by 2030 [9]

Core Insights - The article discusses the upcoming conference titled "Stem Cell Biology: From Embryogenesis to Aging and Therapy," organized by Westlake Laboratory and Westlake University, scheduled for November 19-21, 2025, in Hangzhou, China [1][5]. Conference Details - The conference will focus on the role of stem cells in various biological processes, including embryonic development, tissue homeostasis, and potential therapeutic applications for diseases such as neurodegeneration and organ failure [1]. - Registration for the conference is now open globally, with an extension for poster submissions due to high interest [1]. Academic Committee and Speakers - The academic committee includes prominent figures such as Yu Hongtao, Pei Duanqing, and several distinguished researchers from various institutions [2][4]. - The event will feature keynote speakers from renowned universities, including Linda Partridge from University College London and Toshiro Sato from Keio University, among others [7][10]. Program Structure - The conference will consist of multiple sessions covering topics such as embryogenesis, aging, and stem cell therapy, with a detailed agenda planned for each day [33][35]. - There will be opportunities for poster presentations and a "Meet the Editors" session to facilitate networking and academic collaboration [38]. Registration Fees - The registration fees vary based on the timing and category of participants, with specific rates for students, external registrants, and corporate representatives [41].

Group 1 - The meeting held on November 4 focused on the role of private enterprises in advancing the digital economy and data industry, highlighting the strategic deployment from the 20th Central Committee of the Communist Party of China [1][2] - Private enterprises expressed optimism about the development prospects of the data industry, citing the ongoing reforms in the market-oriented allocation of data elements and the construction of a national integrated data market [1] - The construction of data infrastructure and high-quality data sets is seen as a new tool for enterprises to enhance their digital transformation and connectivity [1] Group 2 - Liu Liehong emphasized the significant advantages of private enterprises in promoting the data industry and artificial intelligence development, encouraging them to actively engage in data-related initiatives [2] - The National Data Bureau aims to create a favorable data policy environment for private enterprises by considering their feedback and continuously enhancing communication [2]

Core Viewpoint - The meeting held by the National Bureau of Statistics emphasizes the importance of private enterprises in advancing the construction of a digital China and encourages them to seize opportunities while expressing confidence in their development [1] Group 1: Government Initiatives - The National Bureau of Statistics, led by Liu Liehong, aims to create a favorable data policy environment for the development of private enterprises [1] - The bureau will actively study the opinions and suggestions put forward by the representatives of private enterprises during the meeting [1] Group 2: Private Enterprises' Role - Ten private enterprises, including Daqian Group and Shenzhen BGI, participated in the meeting, highlighting their commitment to implementing the spirit of the 20th National Congress of the Communist Party [1] - The meeting underscores the expectation for private enterprises to play a larger role in the ongoing digital transformation of the country [1]

证券代码：300676 证券简称：华大基因 公告编号：2025-063 深圳华大基因股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公 司）第四届董事会第七次会议审议通过，公司董事会决定于2025年11月12日（星 期三）召开公司2025年第二次临时股东会。《关于召开2025年第二次临时股东会 的 通 知 》（ 公 告 编 号 ： 2025-061 ） 已 于 2025 年 10 月 24 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn，下同）进行了公告。本次会议将采取现场表决与网 络投票相结合的方式召开，根据相关规定，现就本次会议有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 7、会议出席对象： （1）截至2025年11月6日（星期四）下午收市时，在中国证券登记结算有限 责任公司深圳分公司 ...

Core Viewpoint - The medical sector in A-shares is experiencing a period of adjustment, with mixed performance among individual stocks, but there are signs of potential recovery and growth in earnings and profits in the future [1][3]. Group 1: Market Performance - On November 7, A-shares opened lower, with the Shanghai Composite Index falling below 4000 points, while the medical sector continued its consolidation trend [1]. - The largest medical ETF (512170) showed narrow fluctuations in the morning session, testing support at the six-month line, indicating renewed interest from investors [1]. - After a significant inflow of over 320 million yuan on Tuesday, the ETF attracted an additional 100 million yuan yesterday, suggesting ongoing accumulation by investors [1]. Group 2: Earnings Growth - Analysts predict that the pharmaceutical industry is entering a new cycle of "sustained and high-quality" revenue and profit growth, supported by the ongoing performance recovery in the medical sector [3]. - Among the 50 constituent stocks of the medical ETF (512170), 45 reported profits, with 17 achieving double-digit year-on-year net profit growth. Notably, Zhaoyan New Drug and Meien Health saw net profit growth rates of 214.79% and 110.53%, respectively [3][4]. Group 3: Valuation Insights - The current PE valuation of the medical ETF (512170) stands at 33.29 times, which is still below over 66% of the time in the past decade, indicating potential for valuation recovery [5]. - The medical sector is characterized as a "new quality productive force," poised for high-quality development, with expectations for higher, more certain, and sustained profit quality in the future [4]. Group 4: ETF Overview - As of October 31, 2025, the medical ETF has a scale of 25.6 billion yuan, making it the largest in the market among medical ETFs [6].

Core Viewpoint - The meeting between the Prime Minister of Serbia and the CEO of BGI Group highlights the importance of collaboration in life sciences, agriculture, and education, with a focus on improving the quality of life for the Serbian population [1] Group 1 - The Serbian Prime Minister, Marcut, praised BGI Group's technological strength and its operations in Serbia [1] - Serbia is committed to advancing research and industrial development in the life sciences sector [1] - BGI Group expresses a strong willingness to contribute to major development projects in healthcare, education, and technology in Serbia [1]